{"organizations": [], "uuid": "1bd32ce1297994c6735a5eaf91f3a1b1755f4036", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-palatin-technologies-announces-sub/brief-palatin-technologies-announces-submission-of-bremelanotide-nda-to-fda-idUSASC09TLC", "country": "US", "domain_rank": 408, "title": "BRIEF-Palatin Technologies Announces Submission Of Bremelanotide NDA To FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-26T15:15:00.000+03:00", "replies_count": 0, "uuid": "1bd32ce1297994c6735a5eaf91f3a1b1755f4036"}, "author": "", "url": "https://www.reuters.com/article/brief-palatin-technologies-announces-sub/brief-palatin-technologies-announces-submission-of-bremelanotide-nda-to-fda-idUSASC09TLC", "ord_in_thread": 0, "title": "BRIEF-Palatin Technologies Announces Submission Of Bremelanotide NDA To FDA", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "brief-palatin technologies", "sentiment": "negative"}, {"name": "fda reuters staff", "sentiment": "none"}, {"name": "palatin technologies inc", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26, 2018 / 12:16 PM / Updated 5 minutes ago BRIEF-Palatin Technologies Announces Submission Of Bremelanotide NDA To FDA Reuters Staff 1 Min Read March 26 (Reuters) - Palatin Technologies Inc: * PALATIN TECHNOLOGIES ANNOUNCES SUBMISSION OF BREMELANOTIDE NDA TO FDA FOR TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-26T15:15:00.000+03:00", "crawled": "2018-03-26T15:26:21.004+03:00", "highlightTitle": ""}